Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Reducing Relapse in Severe Alcohol Use Disorder With the NMDA Receptor Antagonist Ketamine


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT02649231

Organisation Name: University College, London

Overal Status: Active, not recruiting

Start Date: October 2016

Last Update: April 15, 2020

Lead Sponsor: University College, London

Brief Summary: 96 recently detoxified alcoholics will be randomized to receive either 3 sessions ketamine (0.8 mg/kg IV over 45 minutes) or placebo plus manualised psychological therapy, or 3 sessions of ketamine or placebo plus simple psychoeducation. Patients will be assessed at 3 and 6 months on a range of psychological and biological variables. Primary endpoints will be % days abstinent at 3 and 6 months and relapse rates at 6 months. Secondary endpoints include depressive symptoms, craving, quality of life.

Conditions:
  • Primary Alcohol Use Disorder


Total execution time in seconds: 0.22086095809937